122 products were found matching "K05097"!

Receptors for VEGF have central roles in vasculogenesis and angiogenesis and thus serve as targets for cancer therapy. Cediranib is a potent inhibitor of VEGF receptor tyrosine kinases, including VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively). It also potently inhibits a variety of other receptor and...

Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay). It also inhibits PDGFRalpha, PDGFRbeta, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional...

Cabozantinib or XL-184 is a tyrosine kinase (c-MET, VEGFR2) inhibitor. It has been shown to reduce tumor growth, metastasis, angiogenesis, and induce apoptosis.

VEGFR inhibitor.

Fruquintinib is a VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively). It also inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases. Fruquintinib inhibits VEGF-A-induced proliferation of human umbilical vein endothelial cells (HUVECs) and...

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRalpha, PDGFRbeta and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces...

ZM 306416 is an inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinase that antagonizes the activity of KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 µM, respectively. It has also been reported to inhibit EGFR kinase with an IC50 value of 98%. Formulation: (Request formulation...

The VEGF receptors (VEGFRs) mediate signaling leading to angiogenesis, with VEGFR3 (FLT4), activated by VEGF isoforms VEGFC and VEGFD, primarily expressed on lymphatic endothelial cells and directing lymphangiogenesis. MAZ51 is an indolinone that selectively antagonizes the activation of VEGFR3 by VEGFC (IC50 = 1...

Light pink to white solid. Soluble in DMSO (>50mg/ml). Slightly soluble in ethanol (1mg/ml). Insoluble in water. Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent, Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, Kit, RET and Raf-1 with IC50 values of...

Tivozanib is an orally available, selective VEGFR inhibitor with IC50 values of 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. It can also inhibit c-Kit and PDGFRbeta with IC50 values of 1.63 and 1.72 nM, respectively. When administered to athymic rats, tivozanib was shown to decrease the...

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib (Cay-18498) by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity. It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRbeta with IC50 values of 1.5, 2.5, 4.2, 7,...

Anlotinib is an orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRbeta, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively). It is selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM). It also inhibits FGFR1 (IC50 = 11.7 nM for...